As the key intermediates in sphingolipid metabolism, we found that the levels of Cer(d18:0/22:0, d18:1/18:0, d18:2/20:2, d36:0, d20:1/18:0) were markedly upregulated in the AD group when compared with the sham-treated group. Here, CBLN1 is linked to Alzheimer disease.